# Clovis Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clovis-oncology

- Industry: Pharmaceuticals
- Headquarters: Boulder, US
- Website: www.clovisoncology.com
- Total disclosed funding: $146M
- Latest round: Series A (May 21, 2009)
- Investors on record: 7

## About

Clovis Oncology, Inc. is an innovative biopharmaceutical company focused on developing targeted therapies for patients with cancer, offering advanced solutions for complex oncological treatments.Founded in 2009 and headquartered in Boulder, US, Clovis Oncology specializes in the development of effective therapeutics for oncology patients. The company went public in November 2011, raising USD 130 mn through an IPO. Patrick Mahaffy serves as the CEO, leading the company in its mission to address unmet medical needs in oncology.Clovis Oncology specializes in developing innovative therapeutics, primarily focused on the treatment of oncology patients. The company’s flagship product is a targeted therapy designed to treat specific types of cancer by inhibiting the growth of cancer cells that have certain genetic mutations. These drugs aim to improve patient outcomes by increasing the efficacy of treatment while minimizing side effects. Clovis Oncology strategically markets its products primarily in North America and Europe, catering to healthcare providers, hospitals, and specialty pharmacies that serve cancer patients. The company aims to address unmet medical needs in oncology, specifically targeting conditions such as ovarian cancer and lung cancer, thereby enhancing the therapeutic options available to oncologists.In the most recent fiscal year 2021, Clovis Oncology reported a revenue of USD 148.76 mn and an EBITDA of USD 236.69 mn. The company generates revenue through the sale of its proprietary oncology therapeutics, distributed directly to healthcare institutions and through partnerships with specialty pharmacies. The revenue model is primarily B2B, involving the sale of therapeutic products to hospitals and clinics that administer these treatments to patients.Clovis Oncology plans to further develop its pipeline of innovative therapies and is actively designing new products to address specific cancer types. The recent funding from the Venture Debt round, which raised USD 300 mn, will support these initiatives, including potential expansion into new geographic markets. The company aims to enhance its presence in North America and Europe while exploring opportunities in emerging markets. The strategic use of this funding will accelerate product development and market penetration efforts.

## Funding rounds

- Series A, May 21, 2009, $146M — Abingworth, Domain Associates, Frazier Healthcare Partners, New Enterprise Associates, Versant Ventures, Aberdare Ventures, ProQuest Investments

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series A
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series A